Genitourinary Cancer in 2023 and Beyond
Expert perspectives and strategic insights on the latest therapeutic developments and translational research in genitourinary cancer treatment. Topics include clinical decision-making and the extent to which emerging data will affect ongoing research, development of new compounds, and future treatment paradigms.
FACULTY CHAIR
Daniel Petrylak, MD
Yale University, New Haven, CT, USA
Faculty Members
Oliver Sartor, MD
Mayo Clinic, Rochester, MN, USA
Neeraj Agarwal, MD, FASCO
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
Scott Tagawa, MD, FASCO, FACP
Weill Cornell Medicine, New York, NY, USA
Leonard G. Gomella, MD, FACS
Thomas Jefferson University, Philadelphia, PA, USA
Robert Dreicer, MD, MACP, FASCO
University of Virginia School of Medicine, Charlottesville, VA, USA
Joaquim Bellmunt, MD, PhD
Harvard Medical School, Boston, MA, USA
Susan Slovin, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Evolving Paradigms in the Management of CSPC and Nonmetastatic CRPC
- Current and Emerging Therapies for mCRPC (Excluding Radiopharmaceuticals)
- Radiopharmaceuticals for Prostate Cancer
- Early-Stage Bladder Cancer (BCG-Resistant NMIBC; MIBC)
- Current Paradigms and Future Directions in Metastatic Bladder Cancer
